Outcomes following immunosuppressive therapy withdrawal after complete renal response in proliferative lupus nephritis
Objective To investigate the rate and factors influencing renal relapse (RR) in proliferative lupus nephritis (LN) patients who discontinued immunosuppressive therapy (IST), as well as the long-term renal outcomes following RR.Methods Retrospective, single-centre study of biopsy-confirmed LN patient...
Saved in:
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMJ Publishing Group
2025-01-01
|
| Series: | Lupus Science and Medicine |
| Online Access: | https://lupus.bmj.com/content/12/1/e001375.full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832592411669299200 |
|---|---|
| author | Javier Narváez Francesca Mitjavila Joan M Nolla Paola Vidal-Montal Montserrat Gomà Xavier Fulladosa Olga Capdevila Joan Torras |
| author_facet | Javier Narváez Francesca Mitjavila Joan M Nolla Paola Vidal-Montal Montserrat Gomà Xavier Fulladosa Olga Capdevila Joan Torras |
| author_sort | Javier Narváez |
| collection | DOAJ |
| description | Objective To investigate the rate and factors influencing renal relapse (RR) in proliferative lupus nephritis (LN) patients who discontinued immunosuppressive therapy (IST), as well as the long-term renal outcomes following RR.Methods Retrospective, single-centre study of biopsy-confirmed LN patients who had received IST for at least 36 months and maintained complete renal response (CRR) for a minimum of 12 months before therapy discontinuation.Results Of a total of 106 patients meeting the inclusion criteria, 76 with proliferative classes were selected for analysis. The median duration of IST prior to discontinuation was 83.5 months (IQR 25th–75th: 53.5–120). Relapse occurred in 29 patients (38.2%) at a median of 26.5 months (IQR 25th–75th: 9.25–63.5 months) following IST withdrawal. Relapses were classified as severe in 9 cases (31%) and moderate in 16 cases (55.2%). Renal rebiopsy was performed in 25 of these patients (86.2%), with 80% retaining the same histological class.Discontinuation of IST at ≤34 years of age significantly increased the risk of RR (adjusted HR: 3.5). In contrast, an IST duration exceeding 48 months prior to discontinuation (HR: 0.26), maintaining CRR for at least 48 months (HR: 0.32), achieving complete remission per DORIS (definition of remission in systemic lupus erythematosus) criteria at IST withdrawal (HR: 0.21) and gradual IST tapering (HR: 0.09) were associated with a reduced risk of RR.Following reintroduction of IST, 20 out of 29 patients (68.9%) achieved CRR, 5 (17.2%) achieved a partial response and 4 (13.8%) did not respond; of these, 3 patients (10.3%) progressed to end-stage renal disease.Conclusions Successful withdrawal of IST is possible in carefully selected patients with proliferative LN. If an RR occurs, most patients are able to remain in remission after resuming IST. |
| format | Article |
| id | doaj-art-596c271770fc421ea070c6e272acd1fb |
| institution | Kabale University |
| issn | 2053-8790 |
| language | English |
| publishDate | 2025-01-01 |
| publisher | BMJ Publishing Group |
| record_format | Article |
| series | Lupus Science and Medicine |
| spelling | doaj-art-596c271770fc421ea070c6e272acd1fb2025-01-21T08:35:13ZengBMJ Publishing GroupLupus Science and Medicine2053-87902025-01-0112110.1136/lupus-2024-001375Outcomes following immunosuppressive therapy withdrawal after complete renal response in proliferative lupus nephritisJavier Narváez0Francesca Mitjavila1Joan M Nolla2Paola Vidal-Montal3Montserrat Gomà4Xavier Fulladosa5Olga Capdevila6Joan Torras7Bellvitge Biomedical Research Institute (IDIBELL), L`Hospitalet de Llobregat, Barcelona, SpainBellvitge Biomedical Research Institute (IDIBELL), L`Hospitalet de Llobregat, Barcelona, SpainDepartment of Rheumatology, Bellvitge University Hospital, L`Hospitalet de Llobregat, Barcelona, SpainBellvitge Biomedical Research Institute (IDIBELL), L`Hospitalet de Llobregat, Barcelona, SpainBellvitge Biomedical Research Institute (IDIBELL), L`Hospitalet de Llobregat, Barcelona, SpainBellvitge Biomedical Research Institute (IDIBELL), L`Hospitalet de Llobregat, Barcelona, SpainBellvitge Biomedical Research Institute (IDIBELL), L`Hospitalet de Llobregat, Barcelona, SpainBellvitge Biomedical Research Institute (IDIBELL), L`Hospitalet de Llobregat, Barcelona, SpainObjective To investigate the rate and factors influencing renal relapse (RR) in proliferative lupus nephritis (LN) patients who discontinued immunosuppressive therapy (IST), as well as the long-term renal outcomes following RR.Methods Retrospective, single-centre study of biopsy-confirmed LN patients who had received IST for at least 36 months and maintained complete renal response (CRR) for a minimum of 12 months before therapy discontinuation.Results Of a total of 106 patients meeting the inclusion criteria, 76 with proliferative classes were selected for analysis. The median duration of IST prior to discontinuation was 83.5 months (IQR 25th–75th: 53.5–120). Relapse occurred in 29 patients (38.2%) at a median of 26.5 months (IQR 25th–75th: 9.25–63.5 months) following IST withdrawal. Relapses were classified as severe in 9 cases (31%) and moderate in 16 cases (55.2%). Renal rebiopsy was performed in 25 of these patients (86.2%), with 80% retaining the same histological class.Discontinuation of IST at ≤34 years of age significantly increased the risk of RR (adjusted HR: 3.5). In contrast, an IST duration exceeding 48 months prior to discontinuation (HR: 0.26), maintaining CRR for at least 48 months (HR: 0.32), achieving complete remission per DORIS (definition of remission in systemic lupus erythematosus) criteria at IST withdrawal (HR: 0.21) and gradual IST tapering (HR: 0.09) were associated with a reduced risk of RR.Following reintroduction of IST, 20 out of 29 patients (68.9%) achieved CRR, 5 (17.2%) achieved a partial response and 4 (13.8%) did not respond; of these, 3 patients (10.3%) progressed to end-stage renal disease.Conclusions Successful withdrawal of IST is possible in carefully selected patients with proliferative LN. If an RR occurs, most patients are able to remain in remission after resuming IST.https://lupus.bmj.com/content/12/1/e001375.full |
| spellingShingle | Javier Narváez Francesca Mitjavila Joan M Nolla Paola Vidal-Montal Montserrat Gomà Xavier Fulladosa Olga Capdevila Joan Torras Outcomes following immunosuppressive therapy withdrawal after complete renal response in proliferative lupus nephritis Lupus Science and Medicine |
| title | Outcomes following immunosuppressive therapy withdrawal after complete renal response in proliferative lupus nephritis |
| title_full | Outcomes following immunosuppressive therapy withdrawal after complete renal response in proliferative lupus nephritis |
| title_fullStr | Outcomes following immunosuppressive therapy withdrawal after complete renal response in proliferative lupus nephritis |
| title_full_unstemmed | Outcomes following immunosuppressive therapy withdrawal after complete renal response in proliferative lupus nephritis |
| title_short | Outcomes following immunosuppressive therapy withdrawal after complete renal response in proliferative lupus nephritis |
| title_sort | outcomes following immunosuppressive therapy withdrawal after complete renal response in proliferative lupus nephritis |
| url | https://lupus.bmj.com/content/12/1/e001375.full |
| work_keys_str_mv | AT javiernarvaez outcomesfollowingimmunosuppressivetherapywithdrawalaftercompleterenalresponseinproliferativelupusnephritis AT francescamitjavila outcomesfollowingimmunosuppressivetherapywithdrawalaftercompleterenalresponseinproliferativelupusnephritis AT joanmnolla outcomesfollowingimmunosuppressivetherapywithdrawalaftercompleterenalresponseinproliferativelupusnephritis AT paolavidalmontal outcomesfollowingimmunosuppressivetherapywithdrawalaftercompleterenalresponseinproliferativelupusnephritis AT montserratgoma outcomesfollowingimmunosuppressivetherapywithdrawalaftercompleterenalresponseinproliferativelupusnephritis AT xavierfulladosa outcomesfollowingimmunosuppressivetherapywithdrawalaftercompleterenalresponseinproliferativelupusnephritis AT olgacapdevila outcomesfollowingimmunosuppressivetherapywithdrawalaftercompleterenalresponseinproliferativelupusnephritis AT joantorras outcomesfollowingimmunosuppressivetherapywithdrawalaftercompleterenalresponseinproliferativelupusnephritis |